Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, discusses the ASCEMBL study results, which suggest that asciminib is a safe and effective drug option for patients with resistance or intolerance to prior therapies. Dr Mauro also points to the need for further research to study asciminib for first- or second-line use, as well as in combination with other therapies.